Analysts Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Price Target at $110.55

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have been assigned an average rating of “Moderate Buy” from the eighteen research firms that are currently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation, twelve have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $110.9091.

A number of analysts have recently weighed in on the company. Canaccord Genuity Group set a $111.00 price objective on Structure Therapeutics in a research note on Friday, August 7th. HC Wainwright dropped their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Citizens Jmp cut their price target on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a report on Friday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen downgraded shares of Structure Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, August 9th.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sterling Capital Management LLC purchased a new position in shares of Structure Therapeutics during the first quarter valued at approximately $28,000. State of Wyoming purchased a new stake in Structure Therapeutics in the second quarter worth $28,000. CWM LLC lifted its stake in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after acquiring an additional 125 shares during the period. Assetmark Inc. boosted its holdings in Structure Therapeutics by 21.4% in the first quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock valued at $123,000 after acquiring an additional 449 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in Structure Therapeutics during the 4th quarter valued at $127,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Trading Up 1.5%

GPCR opened at $54.70 on Friday. Structure Therapeutics has a 12 month low of $18.26 and a 12 month high of $94.90. The business’s 50-day moving average price is $48.88 and its 200-day moving average price is $52.87. The company has a market cap of $3.89 billion, a P/E ratio of -54.70 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Equities research analysts forecast that Structure Therapeutics will post -1.84 earnings per share for the current fiscal year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.